December 14, 2017

CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study

CEL-SCI Corporation recently announced that no further patient enrollment is required in the pivotal Phase 3 head and neck cancer study of its investigational immunotherapy, Multikine. The accrual and treatment phases of this Phase 3 study are complete. 928 patients are enrolled in the study, and are being followed-up as required […]
December 2, 2017

BioFuse’s Technology to “Fuse” Torn or Surgically Divided Tissues

BioFuse Medical Technologies Inc. is a privately-held medical technology and surgical device company that has developed a unique radiofrequency (RF) vessel-sealing platform technology. BioFusion™, the core technology developed by BioFuse Medical Technologies Inc., is an advanced high frequency electrosurgical system which incorporates a unique and proprietary method of controlling and […]
December 2, 2017

NovoCure’s Non-Invasive Cancer Treatment to Target Solid Tumors

Novocure is an oncology company working to develop a novel cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. The […]
December 2, 2017

OneMedForum to Take Hiatus from San Francisco. 11th Annual Conference to Davos, Switzerland

New York — OneMedForum announced that will move to Davos/Klosters Switzerland for 2018 and present research and host sessions on major global health problems for Klosters Innovation Partners during the World Economic Forum January 21-25. Preliminary findings on obesity, cancer and dementia from surveys and interviews with leading investors, scientists, […]
December 2, 2017

China to Reduce Regulations and Boost Pharmaceutical Shares of Traditional Medicine

The support for traditional medicine in China is extremely widespread, with even President Xi Jinping having called this type of medicine a “gem” of the country’s scientific heritage, and promising to give traditional therapies and Western medicine equal government support. Recently, the country began to take dramatic steps to promote […]
December 2, 2017

TapImmune Completes Patient Enrollment in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer

TapImmune Inc., a Florida-based leading clinical-stage immuno-oncology company recently announced that it has enrolled the final patient in a randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV200 for treating triple-negative breast cancer (TNBC). This study is designed to help determine the optimal vaccine dose and regimen […]
December 1, 2017

China BioVentures to Source US Medical Technologies for Large Chinese Companies

Large publicly listed firms are looking to fill product pipeline, with the initial areas of focus including surgical, cancer, dermatology and ophthalmology. On its most recent trip, China BioVentures met with the leadership of large publicly listed companies looking for innovative and proven products. There is a preference for later […]
November 22, 2017

UroGen Pharma’s Immunotherapy Product to Treat High-Grade Non-Muscle Invasive Bladder Cancer

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. They currently have an innovative and broad pipeline of product candidates that they believe can overcome the deficiencies of current treatment options for a […]
November 22, 2017

Altor Bioscience’s Cytokine Technology Platforms to Combat Cancers and Infectious Diseases

Altor BioScience is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer and viral infections, based on its engineered cytokine technology platforms. It was formed in 2002 by Dr. Hing C. Wong as a spin-off from Sunol Molecular Corporation, and is backed by leading venture capital funds, […]
November 21, 2017

Gismo Therapeutics Inc. Receives Two Grants to Develop Novel Therapeutics for Parkinson’s Disease

Gismo Therapeutics Inc. has been awarded two grants to continue their development of therapies to treat Parkinson’s Disease. A $384,000 SBIR grant entitled “Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson’s Therapeutic” was awarded by the National Institute of Neurological Disorders and Stroke (NINDS) – NIH. In addition to this, Gismo Therapeutics […]
November 21, 2017

Excision BioTherapeutics Secures $10 Million in Seed Funding Led by ARTIS Ventures

Excision BioTherapeutics, a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by neurotropic viruses, recently announced it has completed a $10 million seed round of financing, led by ARTIS Ventures. The investment will enable the company to […]
November 21, 2017

Dance Biopharm Announces Buyback of Dance-501 Asia License from Harmony Plus Holdings

Dance Biopharm Holdings, Inc., a privately-held San Francisco-based biotechnology company focused on the development of Dance-501, a proprietary ‘soft-mist’ inhaled insulin product to treat diabetes, recently announced the purchase of Harmony Biopharm Limited, the holder of its Dance-501 Asia license, from Harmony Plus Holdings Limited, an affiliate of Harmony Asset […]
November 21, 2017

Soligenix to Present at the 2017 Biotech and Money Showcase Conference

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, recently announced that its President and Chief Executive Officer, Christopher J. Schaber, PhD, is to deliver a corporate presentation at the 2017 Biotech & Money […]
November 13, 2017

Anthony Gringeri, PhD, CEO of ImmunoCellular Therapeutics, on their Immune-Based Therapies for the Treatment of Cancer

We interviewed Dr. Anthony Gringeri, President and CEO of Immunocellular Therapeutics, a company developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Joining Dr. Gringeri is Dr. Steven Swanson, Senior Vice President […]
November 9, 2017

Philip Young, CEO of Exactus, on their Point-of-Care Diagnostic Tools to Assess Fibrinolysis Status

We interviewed Philip Young, CEO and Chairman of the Board of Exactus Inc., a company specializing in Point-of-Care diagnostics for measuring proteolytic enzymes in the blood based on a novel, proprietary detection platform. Joining Mr. Young is Dr. James Erickson, Chief Business Officer of Exactus. Mr. Young has served as […]
November 3, 2017

The Case for Investing in Orphan Drugs

Investing in biotech companies developing therapeutics seems like a natural decision for physicians and other healthcare providers. One area that should particularly be considered are “orphan drugs” – products being developed for a rare disease. A disease is classified as a “rare disease” if the patient population in the United […]
October 27, 2017

Antinitus featured in 7 News Sydney

Antinitus, a patch designed to reduce the discomfort of tinnitus created by Swedish company Sensori AB, was recently featured on 7 News Sydney. The video follows the progress of three people suffering from tinnitus, and their experience with the Antinitus patch. Tinnitus is classified as an unwanted noise which can […]
August 31, 2017

TapImmune Amends Patient Inclusion Criteria for Phase 2 Clinical Trial

TapImmune (TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women’s cancers has announced that it has amended the patient inclusion criteria for its Phase 2 clinical trial of their T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who […]
August 31, 2017

ProMIS Neurosciences Completes Second Closing of Private Placement

ProMIS Neurosciences Inc. has announced that it has completed the final closing on a non-brokered private placement basis of its previously announced private placement of units of ProMIS Neurosciences for gross proceeds of $1,070,000. In two closings, the ProMIS has raised aggregate gross proceeds of approximately $4,800,000. Regarding this announcement, […]
August 29, 2017

CellAegis Devices Product Delivers Automated Remote Ischemic Conditioning (RIC)

CellAegis Devices is a Toronto-based medical device company that has patented and developed the non-invasive autoRIC Device, which delivers Remote Ischemic Conditioning (RIC) therapy to patients with acute and chronic cardiovascular conditions. Remote ischemic conditioning uses sequences of short, controlled periods of reduced or no blood flow (ischemia) in a […]